Abstract

Deficiencies in the BRCA1 tumor suppressor gene are the main cause of hereditary breast and ovarian cancer. BRCA1 is involved in the Homologous Recombination DNA repair pathway and, together with BARD1, forms a heterodimer with ubiquitin E3 activity. The relevance of the BRCA1/BARD1 ubiquitin E3 activity for tumor suppression and DNA repair remains controversial. Here, we observe that the BRCA1/BARD1 ubiquitin E3 activity is not required for Homologous Recombination or resistance to Olaparib. Using TULIP2 methodology, which enables the direct identification of E3-specific ubiquitination substrates, we identify substrates for BRCA1/BARD1. We find that PCNA is ubiquitinated by BRCA1/BARD1 in unperturbed conditions independently of RAD18. PCNA ubiquitination by BRCA1/BARD1 avoids the formation of ssDNA gaps during DNA replication and promotes continuous DNA synthesis. These results provide additional insight about the importance of BRCA1/BARD1 E3 activity in Homologous Recombination.

Here the authors identify PCNA, a master regulator of DNA replication, as a ubiquitin substrate for the BRCA1/BARD1 heterodimer. This modification is crucial to avoid the appearance of unreplicated DNA gaps in the genome after replication.

Details

Title
BRCA1/BARD1 ubiquitinates PCNA in unperturbed conditions to promote continuous DNA synthesis
Author
Salas-Lloret, Daniel 1   VIAFID ORCID Logo  ; García-Rodríguez, Néstor 2   VIAFID ORCID Logo  ; Soto-Hidalgo, Emily 3   VIAFID ORCID Logo  ; González-Vinceiro, Lourdes 3 ; Espejo-Serrano, Carmen 3 ; Giebel, Lisanne 1 ; Mateos-Martín, María Luisa 4   VIAFID ORCID Logo  ; de Ru, Arnoud H. 5 ; van Veelen, Peter A. 5   VIAFID ORCID Logo  ; Huertas, Pablo 2   VIAFID ORCID Logo  ; Vertegaal, Alfred C. O. 1   VIAFID ORCID Logo  ; González-Prieto, Román 6   VIAFID ORCID Logo 

 Leiden University Medical Centre, Department of Cell and Chemical Biology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
 Universidad de Sevilla, Departamento de Genética, Facultad de Biología, Sevilla, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229); Universidad de Sevilla-CSIC-Universidad Pablo de Olavide-Junta de Andalucía, Andalusian Centre for Regenerative Medicine and Molecular Biology (CABIMER), Sevilla, Spain (GRID:grid.427489.4) (ISNI:0000 0004 0631 1969) 
 Universidad de Sevilla-CSIC-Universidad Pablo de Olavide-Junta de Andalucía, Andalusian Centre for Regenerative Medicine and Molecular Biology (CABIMER), Sevilla, Spain (GRID:grid.427489.4) (ISNI:0000 0004 0631 1969) 
 IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Proteomics Facility, Institute of Biomedicine of Seville, Sevilla, Spain (GRID:grid.414816.e) (ISNI:0000 0004 1773 7922) 
 Leiden University Medical Center, Center for Proteomics and Metabolomics, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000 0000 8945 2978) 
 Leiden University Medical Centre, Department of Cell and Chemical Biology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978); Universidad de Sevilla-CSIC-Universidad Pablo de Olavide-Junta de Andalucía, Andalusian Centre for Regenerative Medicine and Molecular Biology (CABIMER), Sevilla, Spain (GRID:grid.427489.4) (ISNI:0000 0004 0631 1969); Universidad de Sevilla, Departamento de Biología Celular, Facultad de Biología, Sevilla, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229) 
Pages
4292
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3056926619
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.